Free Trial

XTL Biopharmaceuticals Q1 2024 Earnings Report

XTL Biopharmaceuticals EPS Results

Actual EPS
$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XTL Biopharmaceuticals Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

XTL Biopharmaceuticals Earnings Headlines

Your Wealth is Under Attack
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
XTL Biopharmaceuticals Ltd (XTLB)
XTL Biopharmaceuticals Ltd XTLB
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

View XTL Biopharmaceuticals Profile

More Earnings Resources from MarketBeat